Enliven Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-89.02	-71.58	-37.66	-24.74	-18.97
Depreciation & Amortization	0.32	0.3	0.22	0.12	0.05
Other Amortization	-	-	1.74	-	-
Loss (Gain) From Sale of Assets	0.01	-	-	-	-
Loss (Gain) From Sale of Investments	0.42	-4.6	-	-	-
Stock-Based Compensation	20.17	12.91	3.19	1.92	0.13
Other Operating Activities	-0.55	0.31	-	-	9.68
Change in Accounts Payable	0.81	-2.25	0.41	1.73	0.29
Change in Other Net Operating Assets	-5.35	3.65	0.03	1.83	0.29
Operating Cash Flow	-73.19	-61.27	-32.08	-19.13	-8.53
Capital Expenditures	-0.04	-0.15	-0.61	-0.19	-0.46
Investment in Securities	-36.83	-148.26	-	-	-
Other Investing Activities	0.87	-	-	-	-
Investing Cash Flow	-36	-148.41	-0.61	-0.19	-0.46
Issuance of Common Stock	133.17	243.59	0.59	0.69	0.14
Other Financing Activities	-	-9.3	-2.39	-1.71	-
Financing Cash Flow	133.17	234.29	-1.8	-1.02	130.51
Net Cash Flow	23.98	24.61	-34.49	-20.34	121.52
Free Cash Flow	-73.24	-61.42	-32.69	-19.33	-8.99
Free Cash Flow Per Share	-1.56	-1.73	-10.46	-2.47	-1.80
Cash Income Tax Paid	0.23	-	-	-	-
Levered Free Cash Flow	-46.23	-32.95	-17.48	-9.83	-
Unlevered Free Cash Flow	-46.23	-32.95	-17.48	-9.83	-
Change in Net Working Capital	1.33	-5.38	-2.23	-3.8	-

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q